Postes actifs de Dennis Chen
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| PROMIS NEUROSCIENCES, INC. | Corporate Officer/Principal | - | - |
Historique de carrière de Dennis Chen
Anciens postes connus de Dennis Chen
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| GERON CORPORATION | Corporate Officer/Principal | - | - |
Intarcia Therapeutics, Inc.
 Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Corporate Officer/Principal | - | - |
Statistiques
Internationale
| Etats-Unis | 3 |
| Canada | 2 |
Opérationnelle
| Corporate Officer/Principal | 3 |
Sectorielle
| Health Technology | 4 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| PROMIS NEUROSCIENCES, INC. | Health Technology |
| GERON CORPORATION | Health Technology |
| Entreprise privées | 1 |
|---|---|
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
- Bourse
- Insiders
- Dennis Chen
- Expérience
